Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $8.1250 (2.78%) ($8.1250 - $8.1250) on Thu. Feb. 2, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.28% (three month average) | RSI | 75 | Latest Price | $8.1250(2.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA advances 1.3% a day on average for past five trading days. | Weekly Trend | IOVA advances 12.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) XBI(51%) IBB(36%) IWC(30%) ARKG(28%) ACES(26%) | Factors Impacting IOVA price | IOVA will decline at least -2.64% in a week (0% probabilities). VIXM(-15%) EDOC(-12%) UUP(-9%) XLP(-8%) USO(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.64% (StdDev 5.28%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $8.02(1.31%) | 10 Day Moving Average | $7.67(5.93%) | 20 Day Moving Average | $7.01(15.91%) | To recent high | -8.8% | To recent low | 44.8% | Market Cap | $1.19b | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |